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A B S T R A C T
Background: Many patients treated for H. pylori infection
have been taking a proton pump inhibitor beforehand.
There is conflicting evidence whether pretreatment influ-
ences the efficacy of H. pylori eradication. The aim of this
study was to investigate the influence of pretreatment on
cure rates of H. pylori eradication.
Methods: Patients with H. pylori positive peptic ulcer
disease or functional dyspepsia were treated with two-day
quadruple therapy (lansoprazole 30 mg twice daily, and
colloidal bismuth subcitrate 120 mg, tetracycline 250 mg
and metronidazole 250 mg, all eight times a day). Patients
were randomised to receive either three-day pretreatment
with lansoprazole 30 mg twice daily or no pretreatment.
H. pylori was diagnosed using CLO, histology and culture.
Results: Twenty-five (66%) of 38 patients with pretreatment
and 32 (84%) of 38 patients without pretreatment were cured
(p=0.06). After adjustment for diagnosis, smoking status
and metronidazole resistance the influence of pretreatment
became slightly less pronounced (OR 0.44, 95% CI 0.1-1.7).
Nonsmokers and patients with peptic ulcer disease were
more likely to achieve H. pylori eradication than smokers
and patients with functional dyspepsia, respectively
(adjusted odds ratios: 4.79 (1.2-19) and 4.32 (1.0-18)).
Conclusions: This two-day quadruple therapy reached an
overall cure rate of 75%. Nonsmokers and patients with
peptic ulcer disease were more likely to achieve H. pylori
eradication. Three-day pretreatment with a proton pump
inhibitor may decrease cure rates of this two-day quadruple
therapy.
I N T R O D U C T I O N
During the past decade it has been established that not
only patients with peptic ulcer disease but also a sub-
group of patients with functional dyspepsia benefit from
Helicobacter pylori eradication.1,2 Therefore H. pylori test-and-
eradication has been incorporated in most guidelines for
treatment of patients with dyspeptic symptoms.3 As a result,
many patients now receive therapy for H. pylori infection.
Triple and quadruple therapies are usually used and
achieve high cure rates4 but none of the current therapies
have reached a 100% cure in clinical trials5 and several
studies reported that cure rates in routine clinical practice
are even lower.6 Cure rates are influenced by antibiotic
resistance,7 duration of therapy8 and compliance.9
Another factor that has been implicated in therapy failure
is pretreatment with a proton pump inhibitor. This may be
an important factor as many patients treated for H. pylori
infection are already on proton pump inhibitors.10
Although pretreatment was advocated in the assumption
that elevating gastric pH before starting the antibiotics
would increase cure rates, several studies showed that
pretreatment was related to therapy failure for dual therapy
with omeprazole and amoxicillin. Eradication rates were
30 to 70% lower in patients with pretreatment.11-14
The few studies investigating the influence of pretreatment
on triple and quadruple therapies did not find differences
in eradication rates for patients with and without pretreat-
ment.15-17 However, the high eradication rates of seven-day
triple and quadruple therapies make it difficult to study
factors associated with therapy failure.
In this paper we used a very short quadruple therapy to
study the influence of pretreatment. In our area, fairly high
cure rates were reached with this quadruple regimen, and
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because of its short duration we assumed it to be more
vulnerable to the effect of pretreatment. That renders this
regimen suitable for studying the effect of pretreatment
in a fairly small population. The aim of this study was to
evaluate the influence of three-day pretreatment with
lansoprazole on cure rates of a two-day, intensified
quadruple therapy, combining lansoprazole, bismuth,
metronidazole and tetracycline.
M A T E R I A L S  A N D  M E T H O D S
Study population
The study was conducted at Bernhoven Hospital, the
Netherlands, in 1997, with approval of the local ethics
committee. Patients over 18 years with H. pylori positive
peptic ulcer disease or functional dyspepsia were eligible.
Exclusion criteria were use of bismuth compounds/
antibiotics/proton pump inhibitors during the past four
weeks, prior H. pylori eradication, pregnancy or lactation
and known allergic reaction to the study medication. All
participating patients gave written informed consent.
Investigations
All patients underwent upper gastrointestinal endoscopy
both before and four to six weeks after treatment. At
endoscopy seven biopsies were taken: four from the antrum
(two for histology, one for CLO® (Delta West, Australia),
one for culture) and three from the corpus (two for his-
tology and one for CLO®). Biopsies for histological examin-
ation were fixed in neutral buffered 4% formaldehyde and
H. pylori identification was performed on Giemsa-stained
sections of paraffin embedded tissue. For culture Belo-
Horizonte medium was used and plates were incubated
microaerobically for seven days. Resistance to metronid-
azole and clarithromycin was determined by E-test® (AB
Biodisk, Sweden) with cut-off values of 2 and 8 g/ml,
respectively. Patients were considered H. pylori positive
when two out of three tests (CLO®, histology, culture) were
positive. Patients were regarded to be cured when all three
tests were negative.
Patient compliance was assessed both by interview and pill
count. Side effects were registered using the questionnaire
developed by De Boer et al.18
Intervention
Patients received open-label therapy with two-day quadruple
therapy consisting of lansoprazole 30 mg twice daily,
together with colloidal bismuth subcitrate (De-Nol®)
120 mg, tetracycline 250 mg and metronidazole 250 mg
(all taken eight times a day, at 9, 11, 13, 15, 17, 19, 21, and
23 hours). Patients were randomly allocated to three-day
pretreatment with lansoprazole 30 mg twice daily or no
pretreatment at all.
Randomisation procedure
After inclusion each patient received a (sequentially)
numbered, sealed, opaque, envelope containing the
prescription (with or without pretreatment according to
randomisation) and instructions on how to take the drugs.
The envelopes were filled before the start of the study
using a computer-generated randomisation list.
Data analysis
Primary outcome of the study was H. pylori eradication.
The study was designed as a pilot study with 80% power
to detect a 20% decrease in cure rate due to pretreatment,
for an estimated 85% cure rate of this quadruple therapy
without pretreatment (a=0.05).
Baseline characteristics and eradication rates for both
groups were compared using the 2 test. Pretreatment
and baseline characteristics were related to H. pylori
eradication by means of unadjusted and adjusted logistic
regression analyses, using the SAS® statistical software
package (SAS Institute Inc., USA). Statistical significance
was defined as a p<0.05. Missing values were excluded
from analyses.
R E S U L T S
Study population
Altogether, 76 patients were randomised. Table 1 shows the
baseline characteristics of these patients. Unfortunately,
despite adequate randomisation, the pretreatment group
contained more patients with functional dyspepsia.
Janssen, et al. Pretreatment and cure rates of Helicobacter pylori eradication.
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Table 1





Male 21 (55%) 29 (76%)
Female 17 (45%) 9 (24%)
AGE
≤50 years 17 (45%) 14 (37%)
>50 years 21 (55%) 24 (63%)
DIAGNOSIS (p<0.05)
Peptic ulcer disease 14 (37%) 23 (61%)
Functional dyspepsia 24 (63%) 15 (39%)
CURRENT SMOKING 15 (39%) 19 (50%)
ANTIBIOTIC SUSCEPTIBILITY
Metronidazole resistant 7 (23%) 5 (19%)
Metronidazole susceptible 24 (77%) 22 (81%)
Clarithromycin resistant 0 (0%) 0 (0%)
Clarithromycin susceptible 31 (100%) 27 (100%)
Eradication rates, compliance and adverse events
Of 38 patients with pretreatment, 25 (66%) were cured,
whereas 32 (84%) of 38 patients without pretreatment
were cured (p=0.06). All patients reported to have taken
more than 90% of their pills.
The questionnaire on side effects was returned by 67
patients. Eighty-five percent of patients reported ‘no side
effects’, or ‘slight discomfort, not interfering with daily
activities’, 10% reported ‘moderate side effects, some-
times interfering with daily activities’ and 4% reported
‘severe side effects’. None of the patients discontinued
therapy because of side effects. Most frequently reported
side effects were metallic taste, nausea and diarrhoea.
There were no differences in incidence or severity of side
effects between the treatment arms.
Factors associated with treatment outcome
Table 2 shows that there is a tendency towards treatment
failure for patients with pretreatment. For these patients
the risk of treatment failure almost triples, although this
effect becomes somewhat less pronounced after adjust-
ment for diagnosis, smoking and metronidazole resistance.
Furthermore, table 2 shows that diagnosis and smoking
status are important predictors of treatment outcome.
After adjustment, patients with peptic ulcer disease have
an over four times greater chance of treatment success
compared with patients with functional dyspepsia, whereas
smokers have an almost five times greater chance of
treatment failure compared with nonsmokers.
D I S C U S S I O N
The aim of this study was to investigate the influence of
pretreatment with a proton pump inhibitor on H. pylori
eradication. Many patients treated for H. pylori infection
receive pretreatment, either intentionally, in an attempt to
enhance cure rates of H. pylori eradication as used to be
advocated, or unintentionally, by using a proton pump
inhibitor for treatment of gastrointestinal symptoms, peptic
ulcer disease or reflux oesophagitis before starting H. pylori
eradication. This warrants the need to further investigate
the influence of pretreatment.
Theoretically, pretreatment with a proton pump inhibitor
may influence eradication rates in several ways. Firstly,
proton pump inhibitor therapy prevents degradation of
acid labile antibiotics and decreases the minimum
inhibitory concentration of the antibiotics.19
Consequently, pretreatment may increase the effectiveness
of the first doses of antibiotics by elevating gastric pH
before starting eradication therapy. Secondly, proton pump
inhibitor therapy decreases bacterial load, especially in
the antrum.20 This may seem an advantage because less
bacteria have to be killed. However, the remaining bacteria
are in a less active, dormant, state21 and are therefore less
vulnerable to the actions of antibiotics.
In the present pilot study we evaluated the effect of three-
day pretreatment with lansoprazole on eradication rates
of a two-day intensified quadruple therapy. The results
show a trend for patients with pretreatment towards lower
eradication rates. But, although patients with pretreatment
have an 18% lower cure rate, this difference does not reach
statistical significance (p=0.06). This may be due to type II
error, as the power of this pilot study was only sufficient
for detection of a difference of over 20%. Furthermore,
adjustment for diagnosis, smoking status and metron-
idazole resistance slightly decreased the influence of pre-
treatment. This may be explained by the higher number
of patients with functional dyspepsia, who have lower
cure rates than patients with peptic ulcer disease, in the 
pretreatment group.
However, a 10 to 20% decrease may well be possible with
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Table 2
Factors associated with treatment outcome
UNADJUSTED ANALYSIS ADJUSTED ANALYSIS*
FACTOR ODDS RATIO 95% CI P VALUE ODDS RATIO 95% CI P VALUE
Pretreatment (vs no pretreatment) 0.36 0.1-1.1 0.06 0.44 0.1-1.7 0.23
Diagnosis (peptic ulcer disease vs functional dyspepsia) 2.58 0.9-7.8 0.09 4.32 1.0-18 0.05
Smoking (vs no smoking) 0.37 0.1-1.1 0.06 0.21 0.1-0.8 0.03
Metronidazole resistance (resistant vs susceptible) 0.44 0.1-1.7 0.22 0.51 0.1-2.3 0.39
Gender (male vs female) 1.58 0.5-4.6 0.40
Age class (>50 years vs ≤50 years) 1.08 0.4-3.1 0.89
* Adjusted for pretreatment, diagnosis, smoking and metronidazole resistance.
this two-day quadruple therapy. An effect of that magnitude
would be clinically relevant and might have consequences
for clinical practice. Possibly, patients on a proton pump
inhibitor should be advised to either interrupt the proton
pump inhibitor therapy before starting H. pylori eradication
or take an eradication regimen of longer duration.
We used a two-day quadruple therapy in order to be able
to demonstrate the influence of pretreatment without the
necessity to study a large number of patients. Seven-day
quadruple regimens have higher cure rates and may
possibly overcome any deleterious effect of pretreatment.
However, there are no published data on this. For seven-day
proton pump inhibitor triple therapy, two studies investiga-
ting 89 and 101 patients found no difference in cure rates
between patients with and without pretreatment.16,17
However, the high cure rates of these therapies require
large study populations to detect a 10 to 15% difference in
eradication rates. Therefore more research is necessary to
definitely settle the issue of pretreatment.
The overall eradication rate of this two-day quadruple
therapy was 75%, which is comparable with other
research with two-day quadruple therapy.22,23 Although
this is inadequate for use in routine clinical practice,
these results after just two days of therapy emphasise the
efficacy of quadruple therapy.
Being a nonsmoker and having peptic ulcer disease were
associated with a greater chance of achieving H. pylori eradi-
cation. Smoking has been identified by several studies to be
an important factor associated with treatment failure.24-26 The
underlying mechanism is still unknown, although decreased
gastric blood flow,27 damage to the gastric mucosa,28 and
increased acid secretion29 have been implicated.
The higher cure rates for patients with peptic ulcer disease
(vs functional dyspepsia) are consistent with other studies,
typically reporting 5 to 15% higher eradication rates for
patients with peptic ulcer disease.30-32 This may be caused by
the higher prevalence of more virulent H. pylori strains33,34
which cause more inflammation35 in patients with peptic
ulcer disease, as several studies have shown that patients
with more virulent strains36 and with more inflammation37
can be cured more easily.
In conclusion, this two-day quadruple therapy reached an
overall cure rate of 75%. Although this is not sufficient
for use in routine clinical practice, these results after just
two days of therapy emphasise the potency of quadruple
therapy in general. Nonsmokers and patients with peptic
ulcer disease were more likely to achieve H. pylori eradi-
cation. Three-day pretreatment with a proton pump
inhibitor may decrease cure rates of two-day quadruple
therapy, but more research is necessary to definitely
establish the influence of pretreatment with a proton pump
inhibitor on routine therapy for H. pylori eradication.
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